ASBP Aspire Biopharma Holdings, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.22
P/S
18.06
EV/EBITDA
1.44
DCF Value
$-0.51
FCF Yield
-995.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
16.3%
Operating Margin
-15745.9%
Net Margin
-34039.7%
ROE
199.4%
ROA
-165.3%
ROIC
-121.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $28.4K | $-3.2M | $— |
| Q4 null | $4.3K | $-4.7M | $— |
| FY null | $6.2K | $-24.5M | $— |
| Q3 null | $1.9K | $-1.9M | $— |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.21
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.